NextCure Inc. is focused on advancing novel immunomedicines through its proprietary FIND-IO™ technology platform. This innovative approach is designed to identify and develop new therapeutic targets that can enhance the immune system's ability to fight cancer. By leveraging insights from the immune system, NextCure aims to create treatments that are not only effective but also tailored to meet the specific needs of patients, thereby improving outcomes in cancer care.

The company’s commitment to scientific innovation is evident in its robust pipeline of product candidates, which are in various stages of development. NextCure's research emphasizes the importance of understanding the tumor microenvironment and the immune response, allowing for the creation of therapies that can potentially lead to significant advancements in cancer treatment. Through strategic partnerships and a focus on organizational excellence, NextCure is positioned to make a meaningful impact in the field of immuno-oncology.

United States

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Cancer

Central Nervous System (CNS)

Hematologic Diseases

Musculoskeletal Diseases

Nervous System Diseases

NextCure Inc

Colorectal cancer

Ovarian cancer

NC410 is a first-in-class immunomedicine designed to block immune &nbsp;suppression mediated by LAIR-1, an immunomodulatory receptor expressed &nbsp;on T cells and dendritic cells, a type of antigen presenting cell. In &nbsp;preclinical research, it was observed that LAIR-1 inhibited T cell &nbsp;function and dendritic cell activity allowing tumor cells to grow. In &nbsp;preclinical studies, NC410 blocked the negative effects of LAIR-1 and &nbsp;promoted T cell function and dendritic cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.
<a href="http://ir.nextcure.com/news-releases/news-release-details/nextcure-reports-third-quarter-2020-financial-results">Source</a>

NC410 (LAIR-2 fusion)+ pembrolizumab 

Acute myeloid leukemia

Solid tumor/s

NC525 (LAIR-1 mAb)

Breast cancer

Endometrial cancer

LNCB74 is an antibody-drug conjugate that binds specifically to B7-H4, a validated target on tumors.&nbsp; B7-H4 protein is expressed on multiple tumor types, including many cancers specific to women (breast, ovarian and endometrial). LNCB74 has been specifically designed to reduce toxicity while improving tumor killing.&nbsp; Our research showed LNCB74 has potent antitumor activity in CDX and PDX models.

LNCB74 (B7-H4 ADC)

Head and neck squamous cell carcinoma

Triple-negative breast cancer

NC318 is a monoclonal antibody, a first-in-class immunomedicine, targeting Siglec-15 (S15), a novel immunomodulatory protein which is expressed on highly immunosuppressive cells called M2 macrophages and on tumor cells. In preclinical research, we observed that S15 promotes suppression of T cell proliferation and negatively regulates T cell function. NC318 was designed to block S15-mediated immune suppression and restore T cell function and anti-tumor immunity in the TME, which we believe will reduce and kill tumors. We believe NC318 has the potential to treat multiple cancer indications because S15 is expressed in multiple tumor types and has a unique ability to modulate immune responses in the TME. In addition, because S15 and PD-L1 expression in tumors generally appear to be non-overlapping, we believe NC318 may be well suited to treat patients who are not responding to PD-1/PD-L1 directed cancer therapies. NextCure has initiated clinical phase 1/2 clinical trials with NC318 in patient with advanced or metastatic solid tumors.

NC318 (S15) 

NC318 (S15) + pembrolizumab 

Lung cancer

NC762 is a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types. We believe NC762 has unique anti-tumor properties and acts by inhibiting tumor cell growth and killing tumor cells, including by enhancing the immune response. We have observed in preclinical studies that NC762 inhibits the growth of human melanoma tumors in mice, and we believe that NC762 has the potential to treat multiple tumor types. Our research indicates that NC762 inhibits tumor cell growth independently of immune cell infiltration in the TME, but that NK cells may contribute to enhanced anti-tumor activity mediated by NC762.

NextCure Inc

Company Details